WASHINGTON — According to reporting by Geo News, the United States Food and Drug Administration (FDA) has granted formal approval for AstraZeneca’s Imfinzi regimen, establishing a new therapeutic protocol for adults diagnosed with muscle-invasive bladder cancer.
Under the newly approved clinical framework, the pharmaceutical regimen utilizes Imfinzi in direct combination with enfortumab vedotin administered as a neoadjuvant therapy prior to surgical intervention, followed subsequently by Imfinzi monotherapy as post-operative maintenance.
This regulatory milestone expands the clinical applications of immunotherapy in oncology, offering a structured perioperative pathway designed to address aggressive forms of bladder cancer through combined pharmacological and surgical modalities.
With the regulatory clearance now secured, the therapeutic regimen is positioned for integration into standard clinical practice for eligible adult patients, marking a notable advancement in treatment strategies managed by oncology specialists.